These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 17846007

  • 1. [Anti-angiogenic treatment and colorectal cancer].
    André T, Tournigand C, Abbas F, Louvet C, de Gramont A, Gercor (French Oncology Research Group).
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD005392. PubMed ID: 19588372
    [Abstract] [Full Text] [Related]

  • 4. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Yoshida M, Goto M, Kii T, Nishitani H, Kawabe S, Kuwakado S, Asaishi K, Miyamoto T, Higuchi K.
    Digestion; 2013 Jul 08; 87(1):59-64. PubMed ID: 23343971
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T, Lindley C.
    Clin Ther; 2006 Nov 08; 28(11):1779-802. PubMed ID: 17212999
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M, Borg C, Bouché O, Kim S, André T, Bennouna J.
    Bull Cancer; 2015 Sep 08; 102(9):758-71. PubMed ID: 26232849
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E, Schmoll HJ.
    Oncology; 2005 Sep 08; 69 Suppl 3():34-45. PubMed ID: 16301834
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeting angiogenesis in cancer: clinical development of bevacizumab.
    Kerr DJ.
    Nat Clin Pract Oncol; 2004 Nov 08; 1(1):39-43. PubMed ID: 16264798
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Beatty GL, Giantonio BJ.
    Expert Rev Anticancer Ther; 2008 May 08; 8(5):683-8. PubMed ID: 18471041
    [Abstract] [Full Text] [Related]

  • 20. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ.
    Semin Oncol; 2006 Oct 08; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.